Additional reagents and equipment for trypsinizing and counting cells (e.g., CPMB APPENDIX 3F) NOTE: LipofectAMINE and Opti-MEM I are important to the success of the experiment and should not be substituted.
Prepare cells
1. Beginning with a 75-cm 2 tissue culture flask of cells grown to confluence, trypsinize the cells according to standard procedures (e.g., CPMB APPENDIX 3F). LNA, 33, 000 to 39, 000 cells are needed (11, 000 to 13, 000 
The total number of cells (and thus the number of flasks) will depend on the number of LNAs being transfected. For transfection of a single

cells per well at three different concentrations of LNA-LipofectAMINE complex).
2. Suspend the cells in fresh complete growth medium. 3. Draw up the entire volume of cell suspension into a 10-mL pipet and dispense back into the flask with the tip of the pipet pressed lightly against the bottom of the flask.
Aggregates of cells will be disrupted, yielding a single-cell suspension that gives more accurate cell counts.
4. Perform a cell count in triplicate using a Coulter counter or hemacytometer (e.g., CPMB APPENDIX 3F) and average the results.
5. Prepare cell suspension in complete growth medium at a density of 44,000 to 52,000 cells/mL.
6. Plate cells 4 to 6 hr prior to transfection. For each LNA to be transfected, plate 250 µL cell suspension (11,000 to 13,000 cells) in three wells of a 48-well tissue culture plate.
For accuracy with larger numbers of LNAs, use a repeating pipettor and a 12.5-mL Combitip.
7. Replace cover on plate and disperse cells evenly within the wells by sliding the plate back and forth, gently bumping it against the front lip of a laminar flow hood work surface. Keep cells 4 to 6 hr at 37°C in a 5% CO 2 incubator for cells to attach to the surface.
Prepare LNA-LipofectAMINE complexes 8. Warm 100 µM LNA stock solution 5 min at 65°C for a 15-mer or 95°C for a 25-mer to disrupt aggregates, and then maintain at 37°C until transfection. Also warm Opti-MEM I to 37°C.
9. In a 12 × 75-mm round-bottom tube, dilute 6.4 µL of 100 µM LNA with 143.6 µL Opti-MEM I.
10. In a separate 12 × 75-mm round-bottom tube, dilute 1.9 µL LipofectAMINE with 148.1 µL Opti-MEM I. 11. Add 150 µL LipofectAMINE from step 10 to each LNA in step 9 (total 300 µL) and tap the tube briskly 15 times to mix the reagents and initiate the formation of LNA-LipofectAMINE complexes.
12. Allow the tube to sit 15 min at room temperature in the dark.
Opti-MEM I is light sensitive.
Transfect cells
13. While waiting for complexes to form, aspirate off the complete growth medium in each well of the tissue culture plate and replace with 250 µL Opti-MEM I per well. Also set up two tubes for a dilution series of LNA-LipofectAMINE complexes and add 1.5 mL Opti-MEM I to each.
15. Transfer 1.5 mL stock to one of the tubes in step 13 (final 3 mL at 100 nM) and mix well. Transfer 500 µL of this solution to the second tube (final 2 mL at 25 mM) and mix well. 
PREPARATION OF LNA OLIGOMER STOCK SOLUTIONS
LNA oligomers arrive lyophilized and should be handled like DNA or RNA oligomers.
Materials
Locked nucleic acid oligomers (LNAs; Proligo) DNase/RNase-free water (Life Technologies) Spectrophotometer 1. If LNAs have been refrigerated, allow them to equilibrate to room temperature.
2. Centrifuge the samples 2 min at 14,000 × g, room temperature, to collect LNA at the bottom of the tube.
3. Add DNase/RNase-free water to give a stock solution of ∼1 mM. Allow the oligomer to sit undisturbed for 10 to 15 min at room temperature.
The estimated concentration is based on the volume, on the mass reported by the manufacturer, and on the molecular weight of a given LNA.
4. Vortex in 5-sec bursts several times. Heat to 65°C for up to 15 min and cool to room temperature.
5. Allow tubes to sit undisturbed for 5 min, room temperature.
6. Centrifuge 2 min at 14,000 × g, room temperature, to pellet any remaining undissolved material. 2. Prepare a small volume (∼20 to 30 µL) of 100 µM heteroduplex nucleic acid in a solution containing 2.5× CMF-PBS final concentration.
3. Dilute a 5-µL aliquot of the 100 µM heteroduplex mixture with 145 µL of 0.1 M Na 2 HPO 4 buffer, pH 7.5, in a 1-cm-pathlength stoppered cuvette.
4. Overlay this solution with 145 µL mineral oil to minimize evaporation.
5. Monitor the change in the absorbance at 260 nm every 5°C as the temperature is ramped from 100° to 12°C and also back up to 100°C.
6. Fit the data collected from these analyses using van't Hoff thermal denaturation/renaturation curve analysis to determine the T m values from the denaturation and renaturation curves (UNIT 7.3). 10,000 U penicillin 10 mg streptomycin 25 µg/mL amphotericin B (e.g., Fungizone, Invitrogen Life Technologies) Store up to 1 year at −20°C
It is not uncommon for entirely LNA oligomers with >11 bases to possess T m values >95°C.
REAGENTS AND SOLUTIONS
COMMENTARY Background Information
LNAs offer several advantages for nucleic acid recognition (Table 4 .13.1), which should encourage investigators to consider their use. Currently, oligonucleotides that contain LNA bases can be obtained commercially from Proligo (http://www.proligo.com). Synthesis is based on phosphoramidite chemistry and employs LNA monomers of A, T, G, and 5-methyl-C.
The most striking advantage conferred by use of LNA bases is a dramatic increase in the affinity of binding to complementary sequences (Table 4 .13.2). A single LNA base can increase the melting temperature (T m ) of binding by 10°C, and oligomers that contain several strategically positioned LNA bases can bind with even higher affinity than analogous peptide nucleic acid (PNA) oligomers (Braasch and Elayadi, unpub. observ.) . LNA bases are introduced into oligonucleotides by standard synthesis methods (UNIT 4.12), allowing LNA bases to be interspersed among DNA or RNA bases. As a result, important properties such as 
Critical Parameters
When designing oligonucleotides that are intended to function inside cells, the ability of the oligonucleotides to form duplexes that act as substrates for RNase H is a primary consideration (Crooke, 1999) . RNase H degrades RNA-DNA hybrids, allowing oligonucleotides that contain DNA to promote the cleavage of mRNA. If antisense inhibition of gene expression is desired, this can be an advantage since the target mRNA is permanently inactivated, and the antisense oligomer can then move on to inactivate additional mRNA molecules. Oligonucleotides that cannot recruit RNase H (i.e., that do not contain DNA portions) can block the binding of the translation apparatus when targeted to the 5′ terminus of the untranslated region (Baker et al., 1997; Doyle et al., 2001) . Oligomers that do not activate RNase H can also redirect splicing when targeted to splice sites (Kang et al., 1998) , but when they are targeted to other mRNA sequences, they are likely to be displaced by the ribosome.
Oligomers that contain only LNA bases activate RNase H poorly (Wahlestedt et al., 2000) . However, because LNAs are made using protocols similar to those used for DNA synthesis, it is straightforward to incorporate DNA bases into LNA-DNA chimera. This provides the experimenter with the choice of whether or not to incorporate RNase H sensitivity into oligonucleotide design by including a contiguous run of at least six DNA bases. If antisense gene inhibition is desired, this strategy may allow a wider range of sequences to be targeted. If simple steric blocking of the RNA target is required, the potential to direct RNase H cleavage is unnecessary and even counterproductive because it might lead to unintentional destruction of nontargeted RNA substrates.
LNA bases confer some increase in the stability of oligomers to degradation by nucleases. However, to achieve maximal stability in animal studies, it is likely that one or two phosphorothioate (PS) linkages will need to be substituted at both the 3′-and 5′-terminal linkages. As noted above, LNA synthesis is similar to the synthesis of DNA or RNA, allowing PS linkages to be added routinely .
Complete substitution of phosphodiester linkages with PS linkages has also been noted to improve the pharmacokinetic properties of antisense oligonucleotides (Geary et al., 2001) . It is reasonable to believe that LNA-containing oligomers will also need to be modified with PS linkages to achieve in vivo efficacy, though animal studies will be necessary to establish if this truly is the case for LNA-containing chimeric oligonucleotides. The choice of whether or not to exploit the potential for RNase H activation influences how antisense activity will be examined on a case-by-case basis. LNA oligomers that contain DNA segments that can activate RNase H will cause RNA to be degraded, allowing efficacy to be judged by northern analysis. LNA oligomers that cannot activate RNase H can be evaluated by examining the expression of the protein target or by measuring its activity. As with any antisense experiment, use of control oligonucleotides that contain mismatched bases is necessary to support the belief that an effect is specific, i.e., due to binding to the intended mRNA target.
Troubleshooting
When oligonucleotides are introduced into cells, they may prove to be toxic. This toxicity could be due to successful inhibition of the target gene function. However, toxicity could also be due to (1) binding to one or more nontarget proteins, (2) hybridization to one or more nontarget nucleic acid sequences, or (3) poisoning of the cells by small molecule impurities or endotoxins. The primary consideration is that the observed effects should be consistent with the biology of the system being examined.
If cell death is observed, LNAs can be purified by desalting to remove small molecule contaminants. Alternatively, a fresh synthesis of LNA can be performed to determine if newly made material behaves similarly. Toxicity could also be caused by improper choice of transfection conditions, reagent concentrations, cell line, or lipids. The window between the conditions that produce optimal LNA delivery and those that cause cells to die is likely to be small. Use of fluorophore-labeled LNAs provides a convenient method for evaluating the success of a given protocol. The authors have also observed that some syntheses of LNAs are relatively insoluble. If this occurs, the experimenter should consult with the manufacturer.
Anticipated Results
There are many effective antisense oligonucleotides that do not contain LNA bases. Why use LNA? Why not stay with standard oligonucleotide designs? The use of LNAs is only three years old, and there are no definitive answers to these questions. However, it is reasonable to speculate that the ability of LNA bases to dramatically improve the affinity of binding might increase the potency, specificity, and predictability of antisense action. The resulting increase in efficacy would allow "knock down" phenotypes to be generated more easily, and the fact that LNA bases can be easily incorporated into oligonucleotides allows this hypothesis to be readily tested.
Microscopic examination of the delivery of a fluorophore-labeled LNA is a useful demonstration that transfection conditions are promoting LNA uptake by cells. In the authors' experience, micrographs show that LNA is distributed throughout the cytoplasm and nucleus, with some punctate staining indicating areas of high concentration.
Time Considerations
LNAs normally can be obtained within 2 weeks of placing an order with Proligo. LNAs should completely dissolve in water within 20 min. Quantification of LNA concentration by UV spectrophotometry and determination of a T m value should take ∼2 hr. Transfection of LNA into cells should require an additional 2 to 4 hr. The time required for observation of a phenotype will vary from hours to days, depending on the gene being targeted.
